| Hello good day http://www.djoasis.com/writing-a-case-study-analysis-paper/ writing master thesis Morningstar analyst Michael Waterhouse said Teva shares were little affected by the unfavorable court ruling because many analysts and investors had already assumed that Copaxone, which had sales of $4 billion last year, would face competition from at least one generic in 2014.
|